

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00786/048005	SERIAL NO. 08/353,508
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Warren M. Zapol	
(37 CFR 1.98(b))				FILING DATE December 9, 1994	GROUP 3300

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER							ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A.L	AA	4	2	8	7	0	4	0	09/01/81	Alamaro	204	179	
A.L	AB	4	3	3	6	7	9	8	06/29/82	Beran	A61N	128	
A.L	AC	4	8	7	7	5	8	9	10/31/89	O'Hare	422	186.24	
A.L	AD	4	0	1	0	8	9	7	03/08/77	Treharne et al.	239	8	
A.L	AE	4	9	1	5	9	1	5	04/10/90	Treharne et al.	422	186.24	
A.L	AF	4	2	9	7	1	2	3	10/27/81	Wyse et al.	71	58	
A.L	AG	3	7	8	5	3	7	7	01/15/74	Jorgensen	128	188	
A.L	AH	4	6	6	7	6	6	8	05/26/87	Wetterlin	128	203.15	
A.L	AI	4	5	9	2	3	4	8	06/03/86	Waters et al.	128	200.23	
A.L	AJ	4	5	3	4	3	4	3	08/13/85	Nowacki et al.	128	200.23	
A.L	AK	4	8	5	2	5	6	1	08/01/89	Sperry	128	200.23	
A.L	AL	4	9	5	4	5	2	6	9/4/90	Keefer	514	611	
A.L	AM	5	1	5	5	1	3	7	10/13/92	Keefer et al.	514	611	
A.L	AN	5	2	0	8	2	3	3	5/4/93	Keefer et al.	514	231.8	

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
A.L	AO	WO 92/17445	15/10/92	PCT	—	—		
A.L	AP	WO 93/12068	24/06/93	PCT	—	—		
A.L	AQ	GB-A-2 144 997	20/03/85	Great Britain	—	—		
	AR	2178958	2/87	Great Britain				
	AS							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.L	AT	Blomqvist et al., Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator Reversing Human Hypoxic
		Pulmonary Vasoconstriction (HPV), Circulation 84:361, 1991
A.L	AU	Desai et al., Involvement of Nitric Oxide in the Reflex Relaxation of the Stomach to Accommodate food or
		Fluid, Nature 351:477, 1991
A.L	AV	Donahoe et al., Production of O <sub>3</sub> , NO, and N <sub>2</sub> O in a Pulsed Discharge at 1 Atm, Ind. Eng. Chem.
		16:208-215, 1977

EXAMINER

*Warren M. Zapol*

DATE CONSIDERED

3/20/96

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
00786/048005SERIAL NO.  
08/353,508

*MAR 17 1995*  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)  
(37 CFR 1.98(b))

APPLICANT  
Warren M. ZapolFILING DATE  
December 9, 1994GROUP  
*330*

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>AL</i>	BA	Fractacci et al., Inhaled Nitric Oxide, Anesthesiology 75:990-999, 1991
<i>AL</i>	BB	Pepke-Zaba et al., Inhaled Nitric Oxide as a Cause of Selective Pulmonary Vasodilation in Pulmonary Hypertension, The Lancet 338:1173-1174, 1991
<i>AL</i>	BC	Rimar et al., Prolonged Duration of Inhaled Nitric Oxide Induced Vasodilation in Perfused Rabbit Lungs
		Circulation 84:362, 1991
<i>AL</i>	BD	Roberts, Jr. et al., Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator for the Treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), Circulation 84:1279, 1991
<i>AL</i>	BE	Dupuy et al., Bronchodilator Action of Inhaled Nitric Oxide in Guinea Pigs, J. clin. Invest.
		90:421-428, 1992
	BF	Kacmarek et al., Nitric Oxide as a Bronchodilator in Methacholine Induced Bronchospasm in Mild Asthmatics, 1993 ALA/ATS International Conference, May 16-19, 1993, San Francisco, CA #21556 (Abstract)
	BG	Messent et al., The Pulmonary Physician and Critical Care, Thorax 47:651-656, 1992
	BH	Swami et al., the Pulmonary Physician and Critical Care, Thorax 47:555-562, 1992
	BI	Frostell, MD, PhD et al., Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction, Circulation 83:2038-2047, 1991
<i>AL</i>	BJ	Dalby et al., Comparison of Output Particle Size Distributions from Pressurized Aerosols Formulated as Solutions or Suspensions, Pharmac. Re. 5:36-39, 1988
<i>AL</i>	BK	Buga et al., Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle, European J. of Pharmac.
		161:61-72, 1989
<i>AL</i>	BL	Ishii et al., A Simple and Sensitive Bioassay Method for Detection of EDRF with RFL-6 Rat Lung Fibroblasts, Am. J. Physiol. 261:H598-H603, 1991
<i>AL</i>	BM	Stuart-Smith et al., Epithelium, contractile Tone, and Responses to Relaxing Agonists in Canine Bronchi, J. Appl. Physiol. 69:678-685, 1990
<i>AL</i>	BN	Suzuki et al., The Relationship Between Tissue Levels of Cyclic GMP and Tracheal Smooth Muscle Relaxation in the Guinea-Pig, Clinical & Pharmacol. & Physiol. 13:39-46, 1986
EXAMINER	<i>Warren M. Zapol</i>	DATE CONSIDERED <i>3/20/96</i>

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 00786/048005	SERIAL NO. 08/353,508
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Warren M. Zapol		
(37 CFR 1.98(b))		FILING DATE December 9, 1994	GROUP 330	
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)				
A.J.L	CA	Tan et al., Cigarette Smoke Activates Guanylate Cyclase and Increases Guanosine 3', 5' -Monophosphate in Tissues, Science 198:934-936, 1977		
	CB	Maron et al., Cigarette Smoke Causes Acute Fluctuations in the Cyclic GMP Content of the Isolated Intact Lung, Respiration 43:39-44, 1984		
A.J.L	CC	Heaslip et al., Co-Regulation of Tracheal Tone By Cyclic AMP- and Cyclic GMP-Dependent Mechanisms, J. Pharmacol. & Experms. 243:1018-1026, 1987		
	CD	Moncada et al., Nitric Oxide: Physiology, Pathophysiology, and Pharmacology, Pharmacol. Reviews 91:109-141, 1991		
A.J.L	CE	Kalant et al., Drugs and the Respiratory System, Chapter 39 362-397, 1989		
	CF	Gilman et al., Vascular Effects of Cigarette Smoke in Isolated Pig Lungs, Am. Rev. Respir. Dis. 124:549-553, 1981		
A.J.L	CG	Flenley, Today's Treatment of Airway Obstruction.. and Tomorrow's?, Respiration 55:4-9, 1989		
	CH	Physician's Desk Reference, pages 969-971, 2322-2323, 668-670		
A.J.L	CI	Edwards et al., Activation of Hepatic Guanylate Cyclase by Nitrosyl-Heme Complexes, Biomed. Pharmacol. 30:2531-2538, 1981		
	CJ	Garg et al., Nitric Oxide Generating Vasodilators Inhibit Mitogenesis and Proliferation of BALB/C 3T3 Fibroblasts by a Cyclic GMP-Independent Mechanism, Biochem. Biophys. Re. Comm. 171:474-479, 1990		
A.J.L	CK	Schmidt et al., Stimulation of Soluble Coronary Arterial Guanylate Cyclase by Sin-1, European J. Pharmacol. 122:75-79, 1986		
	CL	McNamara et al., Adenosine 3', 5' Monophosphate Formation by Preparations of Rat Liver Soluble Guanylate Cyclase.....and Other Nitroso Compounds, Can. J. Physiol. Pharmacol. 58:1446-1456, 1980		
A.J.L	CM	Ignarro, Biosynthesis and Metabolism of Endothelium-Derived Nitric Oxide, Annu. Rev. Pharmacol. Toxicol. 30:535-560, 1990		
	CN	Allen and Hanbury, Product Information Bulletin on Ventolin, 1990		
EXAMINER A.J.L	Allen and Hanbury, Product Information Bulletin on Ventolin, 1990		DATE CONSIDERED 3/20/96	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
00786/048005SERIAL NO.  
08/353,50817  
1995  
TRADEMARK  
SEARCHEDINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT

Warren M. Zapol

FILING DATE

December 9, 1994

GROUP

3300

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.D.L	DA	Boje et al., Endothelial Nitric Oxide Generating Enzyme(s) in the Bovine Aorta: Subcellular Location
		Location and Metabolic Characterization, Am. Soc. Pharmacol. & Exper. Therapeutics 253:20-26, 1990
A.D.L	DB	Southern et al., Inhibition of Insulin Secretion by Interleukin-1 $\beta$ and Tumor Necrosis Factor- $\alpha$ via an
		L-Arginine-Dependent Nitric Oxide Generating Mechanism, FEBS 276:42-44, 1990
A.D.L	DC	Garg et al., Nitric Oxide-Generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit
		.....Vascular Smooth Muscle Cells, J. Clin. Invest. 83:1774-1777, 1989
Duplicat	DD	<del>Garg et al., Nitric Oxide-Generating Vasodilators Inhibit Mitogenesis and Proliferation of BALB/C 3T3 by a Cyclic GMP-Independent Mechanism, Biochem. Biophys. Res. Comm. 171:474-479, 1990</del>
A.D.L	DE	Brune et al., Activation of a Cytosolic ADP-Ribosyltransferase by Nitric Oxide-Generating Agents,
		J. Biol. Chem. 264:8455-8458, 1989
A.D.L	DF	Curran et al., Nitric Oxide and Nitric Oxide-Generating Compounds Inhibit Hepatocyte Protein Synthesis,
		FASEB J. 5:2085-2092, 1991
A.D.L	DG	Ignarro, Endothelium-Derived Nitric Oxide: Actions and Properties, FASEB J. 3:31-36, 1989
A.D.L	DH	Peckham, Physiologic Factors Affecting Pulmonary Artery Pressure in Infants with Persistent Pulmonary
		Hypertension, J. Ped. 6:1005-1010, 1978
A.D.L	DI	Zapol et al., Pulmonary Circulation During Adult Respiratory Distress Syndrome, Marcel Dekker,
		241-273, 1985
A.D.L	DJ	Fox et al., Pulmonary Hypertension in the Perinatal Aspiration Syndromes, Pediatrics 59:205-211, 1977
A.D.L	DK	Dworetz et al., Survival of Infants with Persistent Pulmonary Hypertension without Extracorporeal Membrane
		Oxygenation, Pediatrics 84:1-6, 1989
A.D.L	DL	Fishman, Pulmonary Hypertension and Cor Pulmonale, Chapter 64 pp. 999-1048
A.D.L	DM	Radermacher et al., Comparison of Ketanserin and Sodium Nitroprusside in Patients with Severe ARDS,
		Anesthesiology 68:152-157, 1988
A.D.L	DN	Vlahakes et al., The Pathophysiology of Failure in Acute Right Ventricular Hypertension: Hemodynamic and
		Biochemical Correlations, Circulation 63:87-95, 1981
EXAMINER	Warren M. Zapol	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00786/048005	SERIAL NO. 08/353,508
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (137 CFR 1.98(b))		APPLICANT		Warren M. Zapol	
		FILING DATE		December 9, 1994	
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)					
A.D.L	EA	Ignarro et al., Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein is Nitric Oxide, Proc. Natl. Acad. Sci. USA 84:9265-9269, 1987			
A.D.L	EB	Palmer et al., Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor, Nature 327:524-526, 1987			
	EC	Ignarro, Biological Actions and Properties of Endothelium-Derived Nitric Oxide Formed and Released From Artery and Vein, Dept. Pharmagy. pp. 23-278			
A.D.L	ED	Higgenbottam et al., Am. Rev. Resp. Dis. Suppl. 137:107, 1988			
A.D.L	EE	Zapol et al., Pulmonary Hypertension in Severe Acute Respiratory Failure, N.E. J. Med. 296:476-480, 1977			
A.D.L	EF	Meyer et al., Nitric Oxide (NO), a New Test Gas for Study of Alveolar-Capillary Diffusion, Eur. Respir. J. 2:494-496, 1989			
A.D.L	EG	Hounam et al., particle Deposition pp. 125-156			
A.D.L	EH	Ignarro, Endothelium-Derived Nitric Oxide: Actions and Properties, FASEB J. 3:31-36, 1989			
A.D.L	EI	Archer et al., Comparison of the Hemodynamic Effects of Nitric Oxide and Endothelium-Dependent Vasodilators in Intact Lungs, J. Appl. Physiol. 68:735-747, 1990			
A.D.L	EJ	Furchtgott et al., Endothelium-Derived Relaxing and Contracting Factors, FASEB J. 3:2007-2018, 1989			
A.D.L	EK	Archer et al., Hypoxic Pulmonary Vasoconstriction is Enhanced by Inhibition of the Synthesis of an Endothelium Derived Relaxing Factor, Biochem. Biophys. Re. Comm. 164:1198-1205, 1989			
A.D.L	EL	Brashers et al., Augmentation of Hypoxic Pulmonary Vasoconstriction in the Isolated Perfused Rat Lung by in Vitro Antagonists of Endothelium-Dependent Relaxation, J. Clin. Invest. 82:1495-1502, 1988			
A.D.L	EM	Ignarro et al., Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide:....S-Nitrosothiols as Active Intermediates, J. Pharmol. Experm. Ther. 218:739-749, 1981			
A.D.L	EN	Kadowitz et al., Pulmonary Vasodilator Responses to Nitroprusside and Nitroglycerin in the Dog, Clin. Invest. 67:893-902, 1981			
EXAMINER	Darcen L. Lewis		DATE CONSIDERED 3/20/96		

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

REPLACEMENT FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00786/048005	SERIAL NO. 08/353,508
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Warren M. Zapol			
		FILING DATE December 9, 1994		GROUP 3300	
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)					
A.D.L	FA	Naeije et al., Effects of vasodilators on Hypoxic Pulmonary Vasoconstriction in Normal Man, Chest 82: 404-410, 1982			
A.D.L	FB	Flavahan et al., Respiratory Epithelium Inhibits Bronchial Smooth Muscle Tone, J. Appl. Physiol. 58:834-838, 1985			
A.D.L	FC	Hugod, Effect of Exposure to 43 ppm Nitric Oxide and 3.6 ppm Nitrogen Dioxide on Rabbit Lung, Int. Arch. Occup. Environ. Health 42:159-167, 1979			
A.D.L	FD	Nakajima et al., Biological Effects of Nitrogen Dioxide and Nitric Oxide, Nitrogen Oxides 121-141			
A.D.L	FE	Packer, Is It Ethical to Administer Vasodilator Drugs to Patients with Primary Pulmonary Hypertension, Chest 95:1173-1175, 1989			
	FF	Agabwal et al., Nature pp. 915-916, 1965			
A.D.L	FG	Stavert et al., Nitric Oxide and Nitrogen Dioxide..... Concentrations for Brief Periods, Inhalation Toxicology 2:53-67, 1990			
A.D.L	FH	Morel et al., Acute Pulmonary Vasoconstriction and Thromboxane Release During Protamine Reversal of Heparin Anticoagulation in Awake Sheep, Circulation Research 62:905-915, 1988			
A.D.L	FI	Morel et al., C5 $\alpha$ and Thromboxane Generation Associated with Pulmonary Vaso-and Broncho Constriction during Protamine Reversal of Heparin, Anesthesiology 66:597-604, 1987			
A.D.L	FJ	Borland et al., A Simultaneous single Breath Measurement of Pulmonary Diffusing Capacity with Nitric Oxide and Carbon Monoxide, Eur. Respir. J. 2:56-63, 1989			
A.D.L	FK	Altabef et al., Intravenous Nitroglycerin for Uterine Relaxation of an Inverted Uterus, Am. J. Obstet. Gynecol. 166:1237-1238, 1992			
	FL	Oxytocin. Prostaglandins. Ergot Alkaloids. Tocolytic Agents., Chapter 39, pp. 942-945			
	FM	Resnick et al., Evaluation and Medical Management of Urinary Incontinence, Anesthesia pp. 3-6, 1992			
	FN	Zapol et al., Regional Blood Flow During Simulated Diving in the Conscious Weddell Seal, J. Appl. Physiol. 47:968-973, 1979			
A.D.L	FO	Contractor et al., Development and Evaluation of an Inhalation Aerosol of Nitroglycerin, J. Pharm. Sci. 63:907-911, 1974			
	FP	Jansen et al., The Relaxant Properties in Guinea Pig Airways of S-Nitrosothiols, J. Pharmacology and Experimental Therapeutics 261:154-160, 1992			
EXAMINER <i>Warren M. Zapol</i>			DATE CONSIDERED 3/20/96		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00786/048005	SERIAL NO. 08/353,508
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Warren M. Zapol			
		FILING DATE December 9, 1994	GROUP <u>3300</u>		
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)					
<u>ADL</u>	GA	Cremona et al., Endothelium-Derived Relaxing Factor and the Pulmonary Circulation, Lung 169:185-202, 1991			
<u>ADL</u>	GB	Dinh Xuan et al., Acetylcholine and Adenosine Diphosphate Cause Endothelium-dependent Relaxation of Isolated Human Pulmonary Arteries, Eur. Respir. J. 3:633-638, 1990			
<u>ADL</u>	GC	Dinh Xuan et al., Primary Pulmonary Hypertension: Diagnosis, Medical and Surgical Treatment, Respiratory Medicine 84:189-197, 1990			
<u>ADL</u>	GD	Dinh Xuan et al., Non-prostanoid Endothelium-derived Vasoactive Factors, J. International Medical Research 17:305-315, 1989			
<u>ADL</u>	GE	Foubert et al., Safety Guidelines for Use of Nitric Oxide, The Lancet 339:1615-1616, 1992			
<u>ADL</u>	GF	Kreye et al., Comparison of Sodium Nitroprusside and Isoprenaline Aerosols in Histamine-Induced Bronchial Asthma of the Guinea Pig, Naunyn-Schmiedeberg S Arch Pharmacol. 306:203-207, 1979			
<u>ADL</u>	GG	Supplementary European Search Report for corresponding EP application NO. 92902708.4, mailed 19 October 1993			
<u>ADL</u>	GH	PCT Search Report from the corresponding PCT Patent Application No. PCT/US93/06091			
	GI				
	GJ				
	GK				
	GL				
	GM				
	GN				
EXAMINER <u>Warren M. Zapol</u>		DATE CONSIDERED <u>3/20/96</u>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
00786/048005SERIAL NO.  
08/353,508INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT  
Warren M. ZapolFILING DATE  
December 9, 1994GROUP 3300

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER			ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA									
	HB									
	HC									
	HD									
	HE									
	HF									
	HG									
	HH									
	HI									
	HJ									
	HK									

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>up to cur</i>	HL	WO/93/12068	24/6/93	PCT				
	HM	WO/92/17445	20/7/92	PCT				
	HN							
	HO							
	HP							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

HQ			
HR			
HS			
EXAMINER	<i>Warren M. Zapol</i>		DATE CONSIDERED <u>3/20/96</u>

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00786/048005	SERIAL NO. 08/353,508								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Warren M. Zapol et al.											
		FILING DATE December 9, 1994		GROUP 3307									
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
<i>A. L.</i>	AA	5	4	2	7	7	9	7	6/27/95	Frostell et al.	424	434	
	AB												
	AC												
	AD												
	AE												
	AF												
	AG												
	AH												
	AI												
	AJ												
	AK												
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION													
		DOCUMENT NUMBER		PUBLICATION DATE	COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	AL												
	AM												
	AN												
	AO												
	AP												
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
	AQ												
	AR												
	AS												
EXAMINER	<i>Warren Lenz</i>				DATE CONSIDERED <i>3/20/96</i>								
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													